The Efficacy of Bisphosphonates for Osteoporosis in Young Cushing's Disease Patients with Biochemical Remission: a Retrospective Cohort Study

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2024 Jul 8

PMID 38974576

Authors

Quanya Sun

Wanwan Sun

Hongying Ye

Shuo Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Patients with Cushing's disease (CD) often experience slow recovery of bone mineral density (BMD), and the effectiveness of anti-osteoporosis drugs in young CD patients who have achieved biochemical remission after surgery is not well understood. Therefore, we aimed to explore whether bisphosphonates could help accelerate the recovery of osteoporosis in young CD patients with remission.

Methods: We retrospectively enrolled 34 young patients with CD who achieved postoperative biochemical remission. All patients suffered from osteoporosis before surgery and were divided into postoperative bisphosphonate treatment group (16 cases) and without bisphosphonate treatment group (18 cases). Clinical data, BMD (Z Value), and bone turnover markers were collected at the time of diagnosis and one year after successful tumor resection.

Results: The Z values in the lumbar spine showed slight improvement in both groups at follow-up compared to baseline, but this improvement was not statistically significant. There was no significant difference observed between the two groups at follow-up. One year after operation, bone formation markers (OC and P1NP) were significantly higher than those at baseline in both groups. However, OC and P1NP in the bisphosphonate treatment group were lower than those in control group at one year follow-up. In without bisphosphonate treatment group, β-CTX from follow-up visit was higher than that at baseline, while no significant difference was observed in the bisphosphonate treatment group before and after surgery.

Conclusion: Young patients with Cushing's disease combined with osteoporosis might not benefit from bisphosphonate therapy for osteoporosis recovery in the first year after achieving biochemical remission.

References

Liu Y, Porta A, Peng X, Gengaro K, Cunningham E, Li H . Prevention of glucocorticoid-induced apoptosis in osteocytes and osteoblasts by calbindin-D28k. J Bone Miner Res. 2004; 19(3):479-90. DOI: 10.1359/JBMR.0301242. View

Dutta A, Gupta N, Walia R, Bhansali A, Dutta P, Bhadada S . Remission in Cushing's disease is predicted by cortisol burden and its withdrawal following pituitary surgery. J Endocrinol Invest. 2021; 44(9):1869-1878. DOI: 10.1007/s40618-020-01495-z. View

Valassi E, Santos A, Yaneva M, Toth M, Strasburger C, Chanson P . The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol. 2011; 165(3):383-92. DOI: 10.1530/EJE-11-0272. View

Kristo C, Jemtland R, Ueland T, Godang K, Bollerslev J . Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing's syndrome: a prospective, long-term study. Eur J Endocrinol. 2005; 154(1):109-18. DOI: 10.1530/eje.1.02067. View

van Houten P, Netea-Maier R, Wagenmakers M, Roerink S, Hermus A, van de Ven A . Persistent improvement of bone mineral density up to 20 years after treatment of Cushing's syndrome. Eur J Endocrinol. 2021; 185(2):241-250. DOI: 10.1530/EJE-21-0226. View

Russell R, Watts N, Ebetino F, Rogers M . Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008; 19(6):733-59. DOI: 10.1007/s00198-007-0540-8. View

Yun S, Yoon H, Jeong S, Chung Y . Glucocorticoid induces apoptosis of osteoblast cells through the activation of glycogen synthase kinase 3beta. J Bone Miner Metab. 2008; 27(2):140-8. DOI: 10.1007/s00774-008-0019-5. View

OBrien C, Jia D, Plotkin L, Bellido T, Powers C, Stewart S . Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 2003; 145(4):1835-41. DOI: 10.1210/en.2003-0990. View

Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz N . Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes Endocrinol. 2021; 9(12):847-875. PMC: 8743006. DOI: 10.1016/S2213-8587(21)00235-7. View

10.

Humphrey M, Russell L, Danila M, Fink H, Guyatt G, Cannon M . 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2023; 75(12):2088-2102. DOI: 10.1002/art.42646. View

11.

Buckley L, Humphrey M . Glucocorticoid-Induced Osteoporosis. N Engl J Med. 2018; 379(26):2547-2556. DOI: 10.1056/NEJMcp1800214. View

12.

Pereira R, Delany A, Canalis E . Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression. Bone. 2002; 30(5):685-91. DOI: 10.1016/s8756-3282(02)00687-7. View

13.

Zhou J, Zhang M, Bai X, Cui S, Pang C, Lu L . Demographic Characteristics, Etiology, and Comorbidities of Patients with Cushing's Syndrome: A 10-Year Retrospective Study at a Large General Hospital in China. Int J Endocrinol. 2019; 2019:7159696. PMC: 6399544. DOI: 10.1155/2019/7159696. View

14.

Braun L, Fazel J, Zopp S, Benedix S, Osswald-Kopp A, Riester A . The Effect of Biochemical Remission on Bone Metabolism in Cushing's Syndrome: A 2-Year Follow-Up Study. J Bone Miner Res. 2020; 35(9):1711-1717. DOI: 10.1002/jbmr.4033. View

15.

Randazzo M, Grossrubatscher E, Dalino Ciaramella P, Vanzulli A, Loli P . Spontaneous recovery of bone mass after cure of endogenous hypercortisolism. Pituitary. 2011; 15(2):193-201. DOI: 10.1007/s11102-011-0306-3. View

16.

Mancini T, Doga M, Mazziotti G, Giustina A . Cushing's syndrome and bone. Pituitary. 2005; 7(4):249-52. DOI: 10.1007/s11102-005-1051-2. View

17.

Hermus A, Smals A, Swinkels L, Huysmans D, Pieters G, Sweep C . Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome. J Clin Endocrinol Metab. 1995; 80(10):2859-65. DOI: 10.1210/jcem.80.10.7559865. View

18.

Ohmori N, Nomura K, Ohmori K, Kato Y, Itoh T, Takano K . Osteoporosis is more prevalent in adrenal than in pituitary Cushing's syndrome. Endocr J. 2003; 50(1):1-7. DOI: 10.1507/endocrj.50.1. View

19.

Di Somma C, Colao A, Pivonello R, Klain M, Faggiano A, Tripodi F . Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease. Clin Endocrinol (Oxf). 1998; 48(5):655-62. DOI: 10.1046/j.1365-2265.1998.00486.x. View